NCT04026360 Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
| NCT ID | NCT04026360 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Confirmed Diagnosis of Cystic Fibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2011-07-01 |
| Primary Completion | 2050-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2011-07-01 with a primary completion date of 2050-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).
Eligibility Criteria
Inclusion Criteria: * Infants with a confirmed diagnosis of CF by NBS * Age \<=18 years * Written informed consent by patient and/or parent Exclusion Criteria: * Need for respiratory support for more than three days * Severe malformations or known diseases other than CF * Maternal drug abuse * Known severe maternal disease * Severe Problems of communication * Pacemaker, continuous glucose monitor
Contact & Investigator
Philipp Latzin, MD PhD
PRINCIPAL INVESTIGATOR
University Children's Hospital Bern
Frequently Asked Questions
Who can join the NCT04026360 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 18 Years, studying Confirmed Diagnosis of Cystic Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04026360 currently recruiting?
Yes, NCT04026360 is actively recruiting participants. Contact the research team at philipp.latzin@insel.ch for enrollment information.
Where is the NCT04026360 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT04026360 clinical trial?
NCT04026360 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Philipp Latzin, MD PhD at University Children's Hospital Bern. The trial plans to enroll 500 participants.